

October 23, 2024

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

<u>Methotrexate for Injection, USP 1g/vial (Preservative-Free)</u> <u>US-Authorized Product – Now Available</u>

Dear Valued Customer.

To help mitigate a drug shortage situation in Canada, Health Canada has permitted the importation and release of Fresenius Kabi's US-authorized Methotrexate for Injection, USP 1g/vial (Preservative-Free).

Healthcare professionals should note that there are differences between the currently approved Canadian product and the product being supplied. Please refer to the following important information:

- 1. The Product Monograph for prescribing information.
- 2. The Risk Communication Letter dated October 23, 2024, describing details and differences between the Canadian– and the US-authorized Methotrexate for Injection, USP 1g/vial.

The Risk Communication and product monograph can be conveniently located on the Fresenius Kabi Canada website at https://www.fresenius-kabi.com/en-ca/.

This product will be available as of October 30, 2024.

Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Pack Size	Availability Date
102250	980833	194204	Fresenius Kabi's US-authorized Methotrexate for Injection, USP 1g/vial (Preservative-Free)	1	October 30, 2024

If you have any questions or for more information, please contact your Sales Representative or our Customer Service Department at: Canada CustomerService@Fresenius-Kabi.com or (877) 821-7724.

Sincerely,

Joseph Le

Associate Director, IV Drugs joseph.le@fresenius-kabi.com

